EM 901

Drug Profile

EM 901

Alternative Names: EM901

Latest Information Update: 04 Nov 2016

Price : $50

At a glance

  • Originator EngMab
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action B-cell maturation antigen modulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 27 Oct 2016 EngMab plans to file an IND with the US FDA for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top